Fox Chase Cancer Center Philadelphia, Pennsylvania
Fox Chase Cancer Center (FCCC) was formed in 1974 by the union of the American Oncologic Hospital, which had been established in 1904, and the Institute for Cancer Research, founded in 1927. Fox Chase became an NCI-designated comprehensive cancer center in 1974. An affiliate of the Temple University Health System since 2012, FCCC is a freestanding cancer center and serves as the Cancer Program for Temple University.
The mission of FCCC is to prevail over cancer by marshalling hearts and minds in bold scientific discovery, pioneering prevention, and compassionate care. With an overall staff of 2,400, the Center provides both care and conducts research in more than 80 laboratories staffed by 325 physicians and scientists. The affiliation with Temple has added value to the cancer center with the addition of 50 research program members from multiple University Departments and the School of Medicine. Clinical, basic, and population research conducted by experts across disciplines in turn enables FCCC to translate new research findings into medical applications that may become models for improved cancer care. FCCC offers the opportunity for participation in clinical trials both at the Center and out in the community, through its Extramural Research Program.
Research programs at the Center encompass Cancer Biology, Blood Cell Development and Function, Molecular Therapeutics, Cancer Epigenetics, and Cancer Prevention and Control.
Among the prevention-related services offered are special programs to help people with family histories or other specific risks of breast and ovarian cancer, gastrointestinal cancer, melanoma, and prostate cancer. FCCC has a dedicated Women’s Cancer Center with a broad spectrum of research programs, treatment, and support.
A notable outreach program is the American-Russian Cancer Alliance (ARCA), a consortium of cancer research institutes led by FCCC for the purpose of bridging scientific research and medical education efforts between the two nations.
* This profile was provided by the Fox Chase Cancer Center.